Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data

Multiple Sclerosis

Volumn 15, Issue 11, 2009, Pages 1372-1373

  Jung, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACCURACY; BLOOD; BLOOD SAMPLING; BODY FLUID; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; LETTER; MEASUREMENT; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; RELIABILITY; URINE;

BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; HUMANS; MATRIX METALLOPROTEINASES; MULTIPLE SCLEROSIS; SERUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 70450195346     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509106855     Document Type: Letter

References (10)

1. Benesová Y., Vasku A., Novotna H., et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as bio-markers of various courses in multiple sclerosis. Mult Scler 2009; 15: 316-322.
2. Zucker S., Doshi K., Cao J. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: Potential clinical applications. Adv Clin Chem 2004; 38: 37-85.
3. Mannello F. Serum or plasma samples? The "Cinderella" role of blood collection procedures: Preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008; 28: 611-614.
4. Jung K., Klotzek S., Stephan C., Mannello F., Lein M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem 2008; 54: 772-774.
5. Mannello F., Jung K., Tonti GA, Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem 2008; 41: 1466-1473.
6. Mannello F., Tonti GA, Canestrari F. The 'neverending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: A landmark for limiting the misuse of serum samples. Mult Scler 2007; 13: 687-690.
7. Mannello F., Tonti GA Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007; 121: 216-218.
8. Makowski GS, Ramsby ML Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 2003; 322: 283-286.
9. Meisser A., Cohen M., Bischof P. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem 2005; 51: 274 - 276.
10. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005; 344: 147-149.